Unknown PHASE1 INTERVENTIONAL 1-arm NCT05765006

CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus

A Phase I Dose-escalation Study Evaluate the Safety Tolerability Pharmacokinetics(PK) and Pharmacodynamics(PD) of Relma-cel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.

Conditions Systemic Lupus Erythematosus

Interventions Relma-cel

Updated 4 times since 2023 Last updated: Mar 12, 2023 Started: Feb 24, 2023 Primary completion: Dec 30, 2024 Completion: Dec 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05765006, this PHASE1 trial focuses on Systemic Lupus Erythematosus and remains ongoing. Sponsored by Shanghai Ming Ju Biotechnology Co., Ltd., it has been updated 4 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Apr 2023 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Feb 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Ming Ju Biotechnology Co., Ltd.

Data source: Shanghai Ming Ju Biotechnology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China